KZR VS INCR Stock Comparison

Performance

KZR
10/100

KZR returned -90.12% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

INCR
10/100

INCR returned -78.13% in the last 12 months. Based on SPY's performance of -13.07%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

KZR
94/100

4 analysts offer 12-month price targets for KZR. Together, they have an average target of 17.5, the most optimistic target put KZR at 21 within 12-months and the most pessimistic has KZR at 14.

INCR
71/100

12 analysts offer 12-month price targets for INCR. Together, they have an average target of 0, the most optimistic target put INCR at 0 within 12-months and the most pessimistic has INCR at 0.

Sentiment

KZR
71/100

KZR had a bullish sentiment score of 71.02% across Twitter and StockTwits over the last 12 months. It had an average of 2.88 posts, 0.88 comments, and 0.62 likes per day.

INCR

"Sentiment" not found for INCR

Technicals

KZR
29/100

KZR receives a 28 of 100 based on 14 indicators. 3 are bullish, 9 are bearish.

INCR
43/100

INCR receives a 42 of 100 based on 14 indicators. 5 are bullish, 7 are bearish.

Earnings

KZR
10/100

KZR has missed earnings 6 times in the last 20 quarters.

INCR
10/100

INCR has missed earnings 5 times in the last 20 quarters.

Profit

KZR
10/100

Out of the last 20 quarters, KZR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

INCR
60/100

Out of the last 20 quarters, INCR has had 12 profitable quarters and has increased their profits year over year on 8 of them.

Volatility

KZR
41/100

KZR has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

INCR
47/100

INCR has had a lower than average amount of volatility over the last 12 months giving it a score of 46 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Kezar Life Sciences, Inc. Common Stock Summary

Nasdaq / KZR

Healthcare

Biotechnology

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.

Intercure Ltd. Ordinary Shares Summary

Nasdaq / INCR

Healthcare

Drug Manufacturers - Specialty & Generic

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.

Power up your portfolio